Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Trepel

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
Oncotarget|September 10, 2016
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcomaChristine M Heske, Arnulfo Mendoza, Leah D Edessa, et al.
BMC Cancer|November 25, 2021
Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancerNorikazu Masuda, Kenji Tamura, Hiroyuki Yasojima, et al.
Plos One|April 5, 2014
High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paragangliomaAlessio Giubellino, Uma Shankavaram, Petra Bullova, et al.
Blood|January 10, 2009
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viabilityCynthia A Pise-Masison, Michael Radonovich, Kathleen Dohoney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2011
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumorsGiuseppe Giaccone, Arun Rajan, Arlene Berman, et al.
Oncogene|June 25, 2002
CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potentialRamon G Manzano, Luis M Montuenga, Mark Dayton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
c-Met ectodomain shedding rate correlates with malignant potentialGagani Athauda, Alessio Giubellino, Jonathan A Coleman, et al.
Journal for Immunotherapy of Cancer|May 5, 2019
Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosisClint T Allen, Sunmin Lee, Scott M Norberg, et al.
Oncotarget|July 23, 2013
Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitorsKristin Beebe, Mehdi Mollapour, Bradley Scroggins, et al.
Cancer Cell|August 16, 2005
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stabilityJennifer S Isaacs, Yun Jin Jung, David R Mole, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
Oncotarget|September 10, 2016
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcomaChristine M Heske, Arnulfo Mendoza, Leah D Edessa, et al.
BMC Cancer|November 25, 2021
Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancerNorikazu Masuda, Kenji Tamura, Hiroyuki Yasojima, et al.
Plos One|April 5, 2014
High-throughput screening for the identification of new therapeutic options for metastatic pheochromocytoma and paragangliomaAlessio Giubellino, Uma Shankavaram, Petra Bullova, et al.
Blood|January 10, 2009
Gene expression profiling of ATL patients: compilation of disease-related genes and evidence for TCF4 involvement in BIRC5 gene expression and cell viabilityCynthia A Pise-Masison, Michael Radonovich, Kathleen Dohoney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2011
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumorsGiuseppe Giaccone, Arun Rajan, Arlene Berman, et al.
Oncogene|June 25, 2002
CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potentialRamon G Manzano, Luis M Montuenga, Mark Dayton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 22, 2006
c-Met ectodomain shedding rate correlates with malignant potentialGagani Athauda, Alessio Giubellino, Jonathan A Coleman, et al.
Journal for Immunotherapy of Cancer|May 5, 2019
Safety and clinical activity of PD-L1 blockade in patients with aggressive recurrent respiratory papillomatosisClint T Allen, Sunmin Lee, Scott M Norberg, et al.
Oncotarget|July 23, 2013
Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitorsKristin Beebe, Mehdi Mollapour, Bradley Scroggins, et al.
Cancer Cell|August 16, 2005
HIF overexpression correlates with biallelic loss of fumarate hydratase in renal cancer: novel role of fumarate in regulation of HIF stabilityJennifer S Isaacs, Yun Jin Jung, David R Mole, et al.
Pageof 5